Background
Nemeroff was born in New York City and graduated from the City College of New York in 1970.
- Photos
- Works
- Photos
- Works
Charles Nemeroff
Edit ProfileEducation
He then earned his Doctor of Philosophy in neurobiology in 1973 and his Doctor of Medicine
Career
He received a Master’s degree in Biology in 1973 from Northeastern University. in 1981, both from the University of North Carolina at Chapel Hill. Nemeroff joined the faculty of Duke University after completing his training, then took a position at the Emory University School of Medicine in 1991. He is the author of numerous textbooks, papers, and clinical studies.
Nemeroff later moved to Florida and become the chair of psychiatry at the University of Miami.
Nemeroff proposed a diathesis-stress model of clinical depression, which suggests that depression is caused by a combination of "vulnerability genes", "resistance genes", and early adverse life events. Nemeroff"s undisclosed ties to drugmakers and under-reported incomes from them have raised questions about conflict of interest.
Following a congressional investigation, Nemeroff was found to be in violation of some federal and university regulations and resigned as chair of the psychiatry department at Emory University. He was also forbidden by Emory to act as an investigator or co-investigator on National Institutes of Health grants for at least two years.
According to the Annals of Neurology, the court documents released as a result of one of the lawsuits against GlaxoSmithKline in October 2008 indicated that GlaxoSmithKline "and/or researchers may have suppressed or obscured suicide risk data during clinical trials" of paroxetine.
Nemeroff stepped down as department chair amid revelations that he had received over $960,000 from GlaxoSmithKline in 2006, yet reported less than $35,000 to Emory University. Subsequent investigations revealed payments totaling more than $2.5 million from drug companies between 2000 and 2006, yet only a fraction was disclosed. In July 2012, GlaxoSmithKline pleaded guilty to criminal charges.
The settlement is related to the company"s illegal promotion of prescription drugs, its failure to report safety data, bribing doctors and using kickback schemes.
